Equities Analysts Issue Forecasts for Brainsway Q1 Earnings

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Analysts at HC Wainwright increased their Q1 2026 earnings per share estimates for Brainsway in a note issued to investors on Thursday, March 12th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.06 per share for the quarter, up from their previous estimate of $0.05. HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Brainsway’s current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for Brainsway’s Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.16 EPS and FY2026 earnings at $0.42 EPS.

A number of other research analysts also recently commented on BWAY. Wall Street Zen raised Brainsway from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Brainsway in a research note on Monday, December 29th. Finally, Northland Securities set a $15.00 target price on shares of Brainsway in a report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, Brainsway currently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Brainsway Stock Performance

NASDAQ:BWAY opened at $13.71 on Monday. The company has a market cap of $537.71 million, a price-to-earnings ratio of 54.84 and a beta of 1.20. Brainsway has a fifty-two week low of $3.92 and a fifty-two week high of $14.65. The stock has a fifty day moving average price of $12.13 and a 200-day moving average price of $9.55.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings data on Wednesday, March 11th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. The firm had revenue of $14.55 million for the quarter, compared to analyst estimates of $14.02 million. Brainsway had a return on equity of 11.10% and a net margin of 14.62%.

Hedge Funds Weigh In On Brainsway

Several hedge funds and other institutional investors have recently modified their holdings of the business. Essex Investment Management Co. LLC raised its holdings in shares of Brainsway by 3.2% during the 3rd quarter. Essex Investment Management Co. LLC now owns 310,684 shares of the company’s stock worth $4,682,000 after buying an additional 9,744 shares in the last quarter. ARK Investment Management LLC acquired a new stake in Brainsway in the fourth quarter valued at about $2,422,000. Y.D. More Investments Ltd grew its position in Brainsway by 559.8% in the fourth quarter. Y.D. More Investments Ltd now owns 114,962 shares of the company’s stock valued at $2,187,000 after acquiring an additional 97,537 shares during the last quarter. Two Sigma Investments LP grew its position in Brainsway by 25.2% in the third quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock valued at $1,551,000 after acquiring an additional 20,706 shares during the last quarter. Finally, Legato Capital Management LLC raised its stake in Brainsway by 9.3% during the fourth quarter. Legato Capital Management LLC now owns 97,376 shares of the company’s stock worth $1,852,000 after acquiring an additional 8,295 shares in the last quarter. Institutional investors own 30.11% of the company’s stock.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.